All In Biotech

Drug Trial Radar · NCT06227910

A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease

A Randomized, Double-Blind, Phase 3b Study to Evaluate the Short- and Long-Term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab and Oral Placebo for Induction Followed by Intravenous Vedolizumab Monotherapy for Maintenance in the Treatment of Adults With Moderately to Severely Active Crohn's Disease

Last checked: Nov 19, 2026Latest source record: May 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 396 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

396

Planned (sponsor's estimate)

Start

Jan 2, 2025

Primary completion

Jun 8, 2027

Study completion Aug 1, 2028

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Jan 29, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main aim of this study is to learn whether vedolizumab and upadacitinib given together (also called dual targeted therapy or DTT) reduces bowel inflammation and ulcers in the bowel compared to vedolizumab only (also called monotherapy) in adults with moderately or severely active Crohn's Disease (CD) after 12 weeks of treatment. Other aims are to learn how safe and effective DTT is compared to monotherapy for these participants. All participants will receive DTT (either vedolizumab and upadacitinib or vedolizumab and placebo) for 12 weeks. Participants responding to the treatment will then receive vedolizumab only (monotherapy) for an additional 40 weeks. During the study, participants will visit their study clinic 15 times.

Conditions

  • Crohn's Disease

Interventions

  • VedolizumabDrug

    Vedolizumab IV infusion.

  • UpadacitinibDrug

    Upadacitinib over-encapsulated tablets.

  • PlaceboDrug

    Upadacitinib matched placebo capsules.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving Clinical Remission Based on the CDAI at Week 12Time frame: Week 12
  2. Percentage of Participants Exhibiting an Endoscopic Response Based on Simple Endoscopic Score for CD (SES-CD) at Week 12Time frame: Week 12

Locations

138 sites in 26 countries. Site status is shown where the registry gives one.

  • UCSD Medical Center

    La Jolla, California · Not yet recruiting

  • Keck Medicine Of USC - USC Healthcare Center 1

    Los Angeles, California · Not yet recruiting

  • Peak Gastroenterology Associates

    Colorado Springs, Colorado · Recruiting

  • GI PROS, Inc.

    Naples, Florida · Active not recruiting

  • Orlando Health Ambulatory Care Center

    Orlando, Florida · Active not recruiting

  • USF Health Morsani Center for Advanced Healthcare

    Tampa, Florida · Active not recruiting

  • Indiana University (IU) Health University Hospital

    Indianapolis, Indiana · Active not recruiting

  • University of Kentucky

    Lexington, Kentucky · Active not recruiting

  • Mount Sinai Hospital - The Susan and Leonard Feinstein Inflammatory Bowel Disease (IBD) Clinical Center

    New York, New York · Active not recruiting

  • Columbia University Medical Center, New York-Presbyterian Hospital

    New York, New York · Not yet recruiting

  • Lenox Hill Hospital Northwell Health

    New York, New York · Active not recruiting

  • Gastroenterology Associates

    Greenville, South Carolina · Active not recruiting

  • Rapid City Medical Center

    Rapid City, South Dakota · Active not recruiting

  • Southern Star Research Institute, LLC

    San Antonio, Texas · Recruiting

  • Tyler Research Institute, LLC

    Tyler, Texas · Recruiting

  • Virginia Mason Medical Center

    Seattle, Washington · Active not recruiting

  • Swedish Cancer Institute

    Seattle, Washington · Not yet recruiting

  • University of Washington Medical Center - Montlake

    Seattle, Washington · Not yet recruiting

  • Medical College of Wisconsin Cancer Center - Froedtert Hospital

    Milwaukee, Wisconsin · Not yet recruiting

  • Johannes Kepler Universitat Linz (JKU)

    Linz, Austria · Not yet recruiting

  • Landeskrankenhaus Salzburg, Innere Medizin I, Labor im Erdgeschoss

    Salzburg, Austria · Not yet recruiting

  • Krankenhaus der Barmherzigen Brueder Wien

    Vienna, Austria · Not yet recruiting

  • Medizinische Universitaet Wien - Allgemeines Krankenhaus der Stadt Wien (AKH) - Universitaetsklinik fuer Innere Medizin III

    Vienna, State of Vienna, Austria · Not yet recruiting

  • Medical University Innsbruck

    Innsbruck, Tyrol, Austria · Not yet recruiting

  • Imelda GI Clinical Research Center

    Bonheiden, Belgium · Active not recruiting

  • Universitair Ziekenhuis Gent

    Ghent, Belgium · Not yet recruiting

  • University Hospitals Leuven

    Leuven, Belgium · Not yet recruiting

  • Centre Hospitalier Chretien MontLegia

    Liège, Belgium · Not yet recruiting

  • Hopital Universitaire de Bruxelles/ Academisch Ziekenhuis Brussel

    Brussels, Anderlecht, Belgium · Not yet recruiting

  • Universidade Federal do Rio de Janeiro (UFRJ)-Hospital Universitario Clementino Fraga Filho (HUCFF)

    Rio de Janeiro, Brazil · Not yet recruiting

  • Hospital das Clinicas of the University of Sao Paulo (Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo (HC/FMUSP))

    São Paulo, Brazil · Not yet recruiting

  • Unidade de Pesquisa Clinica UPC Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto da Universidade de Sao Paulo

    São Paulo, Brazil · Not yet recruiting

  • Hospital Universitario Cajuru

    Curitiba, Paraná, Brazil · Not yet recruiting

  • Faculdade de Medicina de Botucatu

    Botucatu, São Paulo, Brazil · Not yet recruiting

  • Centro de Estudos Clinico do Interior Paulista - CECIP

    Jaú, São Paulo, Brazil · Not yet recruiting

  • Pesquisare Saude

    Santo André, São Paulo, Brazil · Not yet recruiting

  • Heritage Medical Research Clinic - University Of Calgary

    Calgary, Alberta, Canada · Active not recruiting

  • University of Manitoba-Winnipeg Regional Health Authority-Health Sciences Centre

    Winnipeg, Manitoba, Canada · Not yet recruiting

  • Dalhousie University

    Halifax, Nova Scotia, Canada · Not yet recruiting

  • Barrie GI Associates

    Barrie, Ontario, Canada · Recruiting

Showing 40 of 138 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.